384 related articles for article (PubMed ID: 12847388)
1. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Wildt SN; de Hoog M; Vinks AA; van der Giesen E; van den Anker JN
Crit Care Med; 2003 Jul; 31(7):1952-8. PubMed ID: 12847388
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of oral midazolam in preterm infants.
de Wildt SN; Kearns GL; Hop WC; Murry DJ; Abdel-Rahman SM; van den Anker JN
Br J Clin Pharmacol; 2002 Apr; 53(4):390-2. PubMed ID: 11966671
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients.
Ethuin F; Boudaoud S; Leblanc I; Troje C; Marie O; Levron JC; Le Moing JP; Assoune P; Eurin B; Jacob L
Intensive Care Med; 2003 Nov; 29(11):1916-20. PubMed ID: 12923616
[TBL] [Abstract][Full Text] [Related]
4. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.
Swart EL; Zuideveld KP; de Jongh J; Danhof M; Thijs LG; Strack van Schijndel RM
Br J Clin Pharmacol; 2004 Feb; 57(2):135-45. PubMed ID: 14748812
[TBL] [Abstract][Full Text] [Related]
5. Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
Fromm MF; Schwilden H; Bachmakov I; König J; Bremer F; Schüttler J
Eur J Clin Pharmacol; 2007 Dec; 63(12):1129-33. PubMed ID: 17786417
[TBL] [Abstract][Full Text] [Related]
6. Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children.
Bienert A; Bartkowska-Sniatkowska A; Wiczling P; Rosada-Kurasińska J; Grześkowiak M; Zaba C; Teżyk A; Sokołowska A; Kaliszan R; Grześkowiak E
Pharmacol Rep; 2013; 65(1):107-21. PubMed ID: 23563029
[TBL] [Abstract][Full Text] [Related]
7. Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Franken LG; Masman AD; de Winter BCM; Baar FPM; Tibboel D; van Gelder T; Koch BCP; Mathot RAA
Br J Clin Pharmacol; 2017 Aug; 83(8):1701-1712. PubMed ID: 28177137
[TBL] [Abstract][Full Text] [Related]
8. Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study.
Zuppa AF; Conrado DJ; Zane NR; Curley MAQ; Bradfield J; Hakonarson H; Gastonguay MS; Moorthy G; Prodell J; Gastonguay MR
Crit Care Med; 2019 Apr; 47(4):e301-e309. PubMed ID: 30672747
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.
Boulieu R; Lehmann B; Salord F; Fisher C; Morlet D
Eur J Drug Metab Pharmacokinet; 1998; 23(2):255-8. PubMed ID: 9725490
[TBL] [Abstract][Full Text] [Related]
10. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
11. Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.
Aoyama T; Hirata K; Yamamoto Y; Yokota H; Hayashi H; Aoyama Y; Matsumoto Y
J Clin Pharm Ther; 2016 Aug; 41(4):392-8. PubMed ID: 27178380
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of midazolam in critically ill pediatric patients.
Nahara MC; McMorrow J; Jones PR; Anglin D; Rosenberg R
Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):219-21. PubMed ID: 11420893
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study.
Díaz SM; Rodarte A; Foley J; Capparelli EV
Pediatr Crit Care Med; 2007 Sep; 8(5):419-24. PubMed ID: 17693909
[TBL] [Abstract][Full Text] [Related]
14. Proof of Concept: First Pediatric [
van Groen BD; van Duijn E; de Vries A; Mooij MG; Tibboel D; Vaes WHJ; de Wildt SN
Clin Pharmacol Ther; 2020 Nov; 108(5):1003-1009. PubMed ID: 32386327
[TBL] [Abstract][Full Text] [Related]
15. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of interrupted versus continuous sedative infusions in ventilated children.
Gupta K; Gupta VK; Jayashree M; Singhi S
Pediatr Crit Care Med; 2012 Mar; 13(2):131-5. PubMed ID: 21283046
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates.
Ahsman MJ; Hanekamp M; Wildschut ED; Tibboel D; Mathot RA
Clin Pharmacokinet; 2010 Jun; 49(6):407-19. PubMed ID: 20481651
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients.
Malacrida R; Fritz ME; Suter PM; Crevoisier C
Crit Care Med; 1992 Aug; 20(8):1123-6. PubMed ID: 1643892
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration.
Swart EL; de Jongh J; Zuideveld KP; Danhof M; Thijs LG; Strack van Schijndel RJ
Am J Kidney Dis; 2005 Feb; 45(2):360-71. PubMed ID: 15685515
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of fentanyl and midazolam to prevent withdrawal after prolonged sedation in children.
Tobias JD
Crit Care Med; 1999 Oct; 27(10):2262-5. PubMed ID: 10548218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
